Search results
Found 1057 matches for
Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?
Peter Taylor
MA, PhD, FRCP, FRCPE Peter Taylor - Norman Collisson Professor of Musculoskeletal Sciences
Vicki Barber
BSc (Hons) ; FIoB; PhD Vicki Barber - OCTRU Operations Director and Interim Joint CTU Director
David Beard
GDPhys, MCSP, MSc, MA, DPhil, FBOA (hon), FRCS (hon) David Beard - Professor of Musculoskeletal and Surgical Science
Dan Perry
MBChB (Hons), MA(Oxon), PhD, FHEA, FRCS (Orth), FRCSEd (Ad Hominem) Dan Perry - Honorary Professor, Children's Orthopaedics & Trauma Surgery
Sally Hopewell
MSc, DPhil Sally Hopewell - Professor of Clinical Trials and Evidence Synthesis
Joanna Black
BSc, PhD Joanna Black - OCTRU Head of Regulatory Affairs and Quality Assurance (HoRAQ)
Andrew Carr
MA ChM DSc FRCS FMedSci Andrew Carr - Nuffield Professor of Orthopaedics
Susan Wagland
BA, BSc, MSc, PhD Susan Wagland - Clinical Trials Manager
Jonathan Cook
BSc, PhD, CStat Jonathan Cook - Professor of Clinical Trials & Medical Statistics/OCTRU Deputy Director
Rebecca Brehm
MSc Clinical Trials, BSc (Hons) Biological Sciences Rebecca Brehm - Clinical Trial Administrator - Oncology Clinical Trials Office (OCTO)